Cynapsus Therapeutics is a specialty pharmaceutical company developing oral drug treatments for Parkinson's disease. Cynapsus Therapeutics was founded in 2004 and is headquartered in Toronto, Ontario, Canada. On September 1, 2016 Sunovion Pharmaceuticals acquired Cynapsus Therapeutics to expand its own drug portfolio to treat diseases on the central nervous system. Sunovion Pharmaceuticals purchased Cynapsus Therapeutics for approximately $624 million at $40.50 per share in cash.
Cynapsus Therapeutic's drug candidate for the treatment of Parkinson's disease is called APL-130277 and is a sublingual form of apomorphine; a common drug used to treat Parkison's disease that is administered to patients through the gastrointestinal system.
COO & CFO
Anthony J. Giovinazzo
President & CEO, Director
David J. Duff
Dr. Albert Agro
Chief Medical Officer
Vice President Relations & Corporate Communications
Chief Scientific Officer and Executive Vice President of Chemistry, Manufacturing, and Controls
Why Cynapsus Therapeutics (CYNA) Stock Is Soaring Today
Documentaries, videos and podcasts